While anemia has dominated discussions of COVID-19’s hematologic effects, an emerging and clinically important finding is elevated hematocrit in the post-acute phase of infection. As millions of patients recover—or partially recover—from COVID-19, a subset presents with hematocrit values above normal reference ranges. Understanding why this occurs, who is at risk, and what it means clinically is increasingly relevant to post-COVID care.
What Is Hematocrit and What Does “Elevated” Mean?
Hematocrit (HCT) is the percentage of your total total blood volume made up of red blood cells (RBCs). While reference ranges can vary somewhat form one laboratory to the next, normal values are approximately 41–50% in adult males and 36–45% in adult females. Hematocrit above these thresholds—a state called erythrocytosis or polycythemia—indicates either a true increase in RBC mass or a relative increase due to reduced plasma volume. [Note that individuals who live at higher elevations will naturally tend toward having higher HCT values.]
Why COVID-19 Can Drive Hematocrit Up
1. Hypoxia-Driven Erythropoiesis
The most physiologically significant driver of elevated post-COVID hematocrit is chronic or recurrent hypoxia. COVID-19 causes lung injury ranging from mild interstitial inflammation to severe fibrotic damage. Even patients who never required hospitalization can develop persistent pulmonary dysfunction (in the form of reduced diffusion capacity, interstitial changes, and subtle ventilation-perfusion mismatches) that can result in chronically lower oxygen saturations.
When the kidneys detect reduced oxygen delivery, interstitial cells respond by secreting erythropoietin (EPO). EPO stimulates bone marrow to accelerate RBC production. Over weeks to months, this drives hematocrit upward as a compensatory adaptation. This same mechanism is seen in chronic high-altitude exposure and sleep apnea.
Individuals with “silent hypoxemia”—a COVID-19 phenomenon in which oxygen saturation drops significantly without proportionate shortness of breath—can experience weeks of unrecognized low oxygen levels, allowing time for a erythropoietic response.
2. Residual Pulmonary Fibrosis and Impaired Gas Exchange
Post-COVID pulmonary fibrosis, documented by CT imaging and pulmonary function testing, creates a chronically impaired gas exchange surface within the lung. The resulting low-grade hypoxemia becomes a sustained EPO stimulus. Studies at 3-, 6-, and 12-month follow-up intervals have identified compromised oxygen transfer as one of the most persistent of pulmonary symptoms, even in people who had mild illness. Any degree of reduced oxygen transfer that lowers arterial oxygen content can, over time, support compensatory erythrocytosis.
3. Sleep-Disordered Breathing Triggered or Worsened by COVID-19
COVID-19 is associated with new-onset or exacerbated sleep apnea through several mechanisms: upper airway inflammation and edema, neurological effects on respiratory control centers, and weight gain associated with prolonged illness or inactivity. Obstructive sleep apnea (OSA) is one of the most common secondary causes of elevated hematocrit due to the intermittent nocturnal hypoxia it produces. A person who develops OSA as a downstream consequence of COVID-19 may present months later with erythrocytosis that appears disconnected from the original infection.
4. Dysautonomia and Altered Fluid Regulation
Long COVID frequently includes dysautonomia—dysfunction of the autonomic nervous system—manifesting as an intolerance for sitting or standing, an increase in heart rate and lightheadedness upon standing, and inappropriate fluid distribution. Some affected individuals develop a relative reduction in plasma volume, which concentrates the cellular fraction of blood and raises hematocrit without a true increase in RBC mass. This “relative polycythemia” or “stress erythrocytosis” is less concerning than absolute erythrocytosis, but it can still produce hematocrit readings above the normal range.
5. Deconditioning and Reduced Plasma Volume
Prolonged physical inactivity—common during and after COVID-19 illness—reduce overall plasma volume. When patients begin to mobilize and their vascular tone redistributes, measured hematocrit may reflect this contracted plasma state. This is generally transient, but it can persist in individuals with significant deconditioning.
Who Is Most at Risk?
People most likely to develop elevated hematocrit post-COVID include:
- Those with persistent respiratory symptoms or radiologically confirmed pulmonary damage after infection.
- Patients who experienced prolonged hypoxemia during acute illness, particularly those who required supplemental oxygen.
- Individuals with pre-existing conditions such as obesity, sleep apnea, or chronic lung disease, in whom COVID-19 may have worsened baseline hypoxic stress.
- Patients diagnosed with long COVID, especially those with autonomic or cardiopulmonary components.
- Males, who naturally have a higher baseline hematocrit and thus a shorter distance to an elevated status.
Clinical Implications
Thromboembolic Risk
Elevated hematocrit increases blood viscosity, which impairs microvascular flow and raises the risk for developing blood clots. This is particularly concerning in the post-COVID setting, where people may already carry residual hypercoagulability—a well-documented feature of COVID-19 infection linked to endothelial damage, platelet activation, and dysregulation of the coagulation cascade. The combination of elevated hematocrit and post-COVID coagulopathy could synergistically elevate clotting risk.
Cardiovascular Strain
Elevated hematocrit increases cardiac workload. Thickened blood requires greater force to circulate, placing additional demand on the right ventricle—already potentially compromised by COVID-19-associated pulmonary hypertension or myocarditis.
Distinguishing Secondary from Primary Erythrocytosis
Not every post-COVID patient with elevated hematocrit has a hypoxia-driven explanation. Primary polycythemia, caused by a gene mutation, can be coincidentally present or may become clinically apparent for the first time post-COVID.
Management Considerations
- Treat the underlying cause: If hypoxia is driving the erythrocytosis, addressing the pulmonary or sleep pathology (supplemental oxygen, CPAP for OSA, pulmonary rehabilitation) will reduce the EPO stimulus and allow hematocrit to normalize over time.
- Phlebotomy: In patients with elevated hematocrit, therapeutic phlebotomy may be indicated.
- Anticoagulation review: The combination of erythrocytosis and post-COVID hypercoagulability may shift the risk-benefit calculus toward continued or extended use of anticoagulation medications in some people.
- Hydration: Ensuring adequate hydration addresses the relative erythrocytosis component driven by reduced plasma volume and reduces viscosity.
Monitoring and Follow-Up
Post-COVID patients with known pulmonary involvement or documented hypoxemia during acute illness should have hematocrit checked at follow-up visits, particularly at the 3- and 6-month marks. Trending hematocrit alongside pulmonary function tests, oxygen saturation on exertion, and inflammatory markers provides a more complete picture of recovery trajectory and residual risk.
How Is This Related to Hormone Therapy?
In some men, testosterone replacement therapy stimulates the body to produce an excess of red blood cells. The result over time can be elevated hematocrit. An increase in HCT does not mean these men have to discontinue their testosterone therapy. However, it does mean therapeutic phlebotomy at regular intervals (usually in the form of a routine blood donation) will be part of their treatment regimen/protocol. At Renew Youth, this has been a standard component of properly executed testosterone therapy for decades.
Because we routinely and regularly monitor HCT within our client population (for the reason noted above), we can anecdotally report an increased number of our male clients presenting with elevated HCT since 2020 (when COVID got under way). For those who tended toward having elevated HCT as a consequence of their testosterone therapy pre-COVID, we have observed that for many of these individuals it has become a somewhat more persistent issue (requiring more frequent therapeutic phlebotomy). And perhaps even more interesting, since 2020, we are routinely seeing elevated HCT among our female clients.
This means that an increasing number of elevated HCT cases we’re seeing are not caused (or at least not entirely caused) by testosterone replacement therapy.
Regardless, our proximity to the data (combined with our insight and expertise) positions us well to provide clinical guidance (particularly as it relates to therapeutic phlebotomy) to those who are affected.
At Renew Youth, our focus is hormone therapy and longevity medicine—but not to the exclusion of everything else. Would you like to have us in your corner? Call us at (800) 859-7511 or use our easy contact form to schedule your complimentary 30-minute consultation.